BioCryst Pharmaceuticals BCRX Finance Lease Interest Payment On Liability
Finance Lease Interest Payment On Liability at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseInterestPaymentOnLiability.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's finance lease interest payment on liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's finance lease interest payment on liability?
- BioCryst Pharmaceuticals (BCRX) reported finance lease interest payment on liability of $64K in Q1 2026.
- How has BioCryst Pharmaceuticals's finance lease interest payment on liability changed year-over-year?
- BioCryst Pharmaceuticals's finance lease interest payment on liability decreased by 31.9% year-over-year, from $94K to $64K.
- What is the long-term trend for BioCryst Pharmaceuticals's finance lease interest payment on liability?
- Over 3 years (2021 to 2025), BioCryst Pharmaceuticals's finance lease interest payment on liability has grown at a 39.6% compound annual growth rate (CAGR), from $125K to $340K.
- What does finance lease interest payment on liability mean?
- This represents the cash interest portion of payments made toward finance lease obligations. It isolates the cost of borrowing inherent in the lease structure, distinct from the principal repayment. Monitoring this helps in evaluating the company's debt-servicing requirements related to leased assets.